SBIR/STTR Research Award

BEDSIDE SYSTEM FOR COMBINED RNA AND PACIN HEART FAILURE

Award identifier 172afdf40be559b41f8913758361451a98957cd7a97252caefe12f787de1aaabAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROPORTIONAL TECHNOLOGIES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
TAPPXED88F63
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by Applicant): One of the most significant current health care challenges is treatment of heart failure (HF). There are approximately 5 million Americans currently diagnosed with this condition, and there are 400,000-700,000 new cases annually. The direct costs of treatment are estimated at $10-$38 billion with the majority of this cost attributable to patients with New York Heart Association Class III or IV disease. Much of this cost is a result of repeat hospitalization, which occurs in many cases because of inappropriate therapeutic drug regimen. This proposal seeks to develop a technology for combined bedside radionuclide angiography (RNA) and pulmonary artery catheterization (PAC) that can be employed in this population at reasonable cost in the CCU. By merging RNA and PAC, this system will yield LV and RV ejection fractions, right heart, pulmonary, and left atrial pressures, cardiac output, stroke volume, wall motion, pulmonary blood volume, and, most significantly, absolute RV and LV volume curves, so that pressure-volume relations can be examined. By providing this wealth of additional clinical data, which can be obtained repeatedly at low cost through use of a short-lived radiotracer, this system will enable much more thorough evaluation of such patients, including quantitative examination of the effects of interventions, such as dobutamine and IV diuretics, as well as assessments of response to therapeutic dose levels. It will therefore lead to improved diagnosis, allow drug dose levels to be more accurately determined, and improve prognostic assessment. Since much of the cost of this disease is attributable to the need for repeated hospitalization of decompensated patients, substantial reduction of overall cost can be realized. Improved prognostic evaluation can also have a profound benefit by more accurately identifying patients who are suitable for heart transplantation and/or coronary artery bypass. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

55 SBIR/STTR records share this UEI (1994–2023). Reported award amounts total $25,350,343. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Energy, Department of Defense, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.